Anti-Erythropoietin Receptor (EPOr)

The Human Erythropoietin Receptor (EPOr) is located on stem and mature cells of the hematopoietic system. When activated by its native ligand, Erythropoietin, EPOr mediate proliferation and maturation of the erythroid precursor cells leading to expansion of red cell populations. Human recombinant EPO is currently used for treatment of patients undergoing erythrocyte depletion due to dialysis for kidney failure. , Applications: Suitable for use in Immunoprecipitation, Western Blot, Neutralization, Immunohistochemistry, Immunocytochemistry and ELISA. Other applications not tested. Recommended Dilution: Immunoprecipitation: 10ug/ml, Western Blot: 10ug/ml, Neutralization: 500ug/ml. Neutralization of ligand binding has been detected using erythroleukemia cell line TF-1 with 3000 Epo receptors/cell to block Iodine 125 labeled erythropoietin ligand binding. , Immunohistochemistry: 10ug/ml, Immunocytochemistry: 10ug/ml, ELISA: 50ng/ml, Optimal dilutions to be determined by the researcher. Recommended Secondary Antibodies: I1904-59C: IgG, H&L (HRP) Pab RbxSh, I1904-59HI: gG, H&L, X-Adsorbed (HRP) Pab RbxSh, Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.